MRPMedical Research and Practice2993-96902993-9704Art and Technology10.61369/MRP.8021ArticleⅣ期肺癌患者多模式镇痛研究进展https://artdesignp.com/journal/MRP/2/8/10.61369/MRP.8021李美华,张惠然,吴晓徹,郭铁标2024282024-08-20肺癌作为中国乃至全球癌症疾病负担的重要组成部分，其患者疼痛管理的优化成为临床关注的焦点。基于2022年全国癌症统计数据，本文旨在综述中国肺癌患者疼痛管理的现状，以患者自控镇痛（PCA）技术为载体，探讨多模式镇痛策略包括非甾体类药物、阿片类药物的合理应用，以及新型药物如右美托咪定的联合使用，为肺癌患者提供了有效的疼痛控制手段。未来，多模式镇痛策略的优化，包括药物创新、技术进步与跨学科合作，对于提升肺癌患者的生活质量至关重要。肺癌疼痛 ,多模式镇痛 ,非甾体类药物 ,阿片类药物 ,患者自控镇痛

[1] Rongshou Zheng, Siwei ZhangCancer,et al.incidence and mortality inChina, 2016,［J］．Journal of the National Cancer Center,2022,Volume2,(Issue1,):Pages1-9.[2] ZhangB,LiX,MaZ,et al.Prevalence and management of pain in lung cancerpatients in northern China: a multicenter cross-sectional study［J］．ThoracCancer,2022,13(11):1684-1690.[3] 刘晓琳，朱冠雅．规范化癌痛干预对晚期肺癌患者癌痛程度、心理状态及生活质量的影响［J］．癌症进展，2023,21(04):435-438+450.[4] 杨薏帆， 冯艺．非甾体抗炎药在癌痛治疗中的进展［J］．中国疼痛医学杂志，2020,26(06):443-446.[5] Wang, Y. et al. (2023). “Combination therapy with NSAIDs and opioids for cancerpain relief: A meta-analysis.” Pain Medicine, 24(1), 23-30.[6] Anonymous. WHO analgesic ladder. www.who.int/cancer/palliative/painladder/en/ (accessed 10 April 2017).[7] Corder, G., et al. (2018). Endogenous and exogenous opioids in pain. Annualreview of neuroscience, 41, 453-473.[8] Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients:ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv166-iv191.[9] Wan, Z., Chu, C., Zhou, R. and Que, B. (2020) Effects of Oxycodone CombinedWith Flurbiprofen Axetil on Postoperative Analgesia and Immune Function inPatients Undergoing Radical Resection of Colorectal Cancer. Clinical Pharmacologyin Drug Development, 10, 251-259.[10] Gupta, A., et al. (2022). Synergistic Effect of Ketorolac and Bupivacaine forPostoperative Analgesia in Breast Surgery: A Randomized Controlled Trial. RegionalAnesthesia & Pain Medicine, 47(4), 231-236.[11] Keating, G. M. (2015). Dexmedetomidine: A Review of Its Use for Sedation inthe Intensive Care Setting. Drugs, 75(10), 1119-1130.[12] Funai, Y., et al. (2014). Systemic dexmedetomidine augments inhibitorysynaptic transmission in the superficial dorsal horn through activation of descendingnoradrenergic control: An in vivo patch-clamp analysis of analgesic mechanisms.Pain, 155(3), 617-628.[13] Wang, L., et al. (2023). Low-Dose Continuous Subcutaneous DexmedetomidineInfusion for Chronic Pain Management in Advanced Lung Cancer: A ProspectiveStudy. Supportive Care in Cancer, 31(2), 1-9.[14] Kondasinghe JS, Tuffin PHR, Findlay FJ. Subcutaneous patient-controlled analgesiain palliative care［J］．J Pain Palliat Care Pharmacother, 2021, 35(3):163-166.[15] 王昆，邵月娟，金毅，等．患者自控镇痛治疗癌痛专家共识［J］．中国肿瘤临床，2023,50(15):757-763.